MK-677 and YK-11 Interaction

Synergistic
Researched 95% confidence

MK-677 and YK-11 have a synergistic interaction with 95% confidence. MK-677 (Ibutamoren) is frequently combined with YK-11. MK-677 increases growth hormone and IGF-1 through ghrelin receptor agonism, which complements YK-11's AR-mediated and follistatin-mediated anabolic mechanisms through a completely independent pathway. MK-677 does not suppress testosterone and is not hepatotoxic, making it one of the safer adjuncts to a YK-11 cycle. The combination may enhance lean mass gains, recovery, and joint comfort (via GH-mediated collagen synthesis), potentially offsetting YK-11's reported joint dryness. These compounds primarily affect different organ systems.

Compound Profiles

MK-677

Ghrelin Receptor Agonist | Oral Growth Hormone Secretagogue

Selectively binds GHS-R1a receptors in hypothalamus and pituitary, triggering pulsatile growth hormone release while maintaining natural circadian patterns..

Half-life: ~24 hours Typical dose: Start 12.5mg daily, increase to 25mg based on tolerance growth hormone, weight loss, sleep
ghrelin receptor blood pressure raisingcarcinogenic riskhepatotoxicinsulin disrupting
View full profile

YK-11

Myostatin Inhibitor & SARM Hybrid | Experimental

YK-11 exerts its effects through two distinct but complementary pathways. First, it acts as a partial agonist of the androgen receptor (AR).

Half-life: ~6-10 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptormyostatintgf beta androgenicblood pressure raisingcarcinogenic riskhepatotoxic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Brain
low
GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds raise blood pressure (MK-677, YK-11). Monitor BP daily and consider cardiovascular support.
2x 2 compounds share the carcinogenic-risk safety flag (MK-677, YK-11). Monitor accordingly.
2x 2 hepatotoxic compounds (MK-677, YK-11). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (MK-677, YK-11). Monitor accordingly.

Frequently Asked Questions

Can I take MK-677 with YK-11?

Yes, MK-677 and YK-11 can generally be taken together. MK-677 (Ibutamoren) is frequently combined with YK-11. MK-677 increases growth hormone and IGF-1 through ghrelin receptor agonism, which complements YK-11's AR-mediated and follistatin-mediated anabolic mechanisms through a completely independent pathway. MK-677 does not suppress testosterone and is not hepatotoxic, making it one of the safer adjuncts to a YK-11 cycle. The combination may enhance lean mass gains, recovery, and joint comfort (via GH-mediated collagen synthesis), potentially offsetting YK-11's reported joint dryness.

Is MK-677 and YK-11 safe together?

Based on documented research, this combination is considered synergistic. However, shared safety flags include: blood pressure raising, carcinogenic risk, hepatotoxic, teratogenic. Monitor accordingly.

What are the interactions between MK-677 and YK-11?

MK-677 (Ibutamoren) is frequently combined with YK-11. MK-677 increases growth hormone and IGF-1 through ghrelin receptor agonism, which complements YK-11's AR-mediated and follistatin-mediated anabolic mechanisms through a completely independent pathway. MK-677 does not suppress testosterone and is not hepatotoxic, making it one of the safer adjuncts to a YK-11 cycle. The combination may enhance lean mass gains, recovery, and joint comfort (via GH-mediated collagen synthesis), potentially offsetting YK-11's reported joint dryness. This assessment has 95% confidence and is based on documented research data.

How should I time MK-677 and YK-11?

MK-677 has a half-life of ~24 hours and YK-11 has a half-life of ~6-10 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: MK-677 vs YK-11

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.